



RECEIVED

MAR 28 2003

TECH CENTER 1600/2900

Express Mail No.: EL 501 759 564 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Schneider and Klein

Confirmation No.: 7849

Application No.: 09/955,006

Group Art Unit: 1648

Filed: September 17, 2001

Examiner: B. Li

For: INHIBITION OF THE SRC KINASE FAMILY
PATHWAY AS A METHOD OF TREATING
HBV INFECTION AND HEPATOCELLULAR
CARCINOMA

Attorney Docket No.: 5914-084-999

AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the outstanding Office Action mailed September 20, 2002, please consider the amendments and remarks below. Applicants submit herewith: (a) Petition for Extension of Time; (b) Wood, 1999, *NE J. Med.* 341:1447-57 attached hereto as Exhibit 1; (c) Chapter 20 of The Handbook of Fluorescent Probes and Research Chemicals published by Molecular Probes attached hereto as Exhibit 2; (d) pages 454-461 of the Physicians' Desk Reference 55th edition 2001, attached hereto as Exhibit 3 (e) a marked-up version of the amended paragraphs as Appendix A; (f) a marked-up version of the claims amended herein as Appendix B; and (g) a copy of the claims as pending in the present application after entry of the present amendment as Appendix C.

IN THE SPECIFICATION

Please amend the specification to read as follows:

On page-7, please replace the second paragraph with the following:

The Applicants have shown that HBx activation of Src kinases stimulates viral DNA replication, and HBx activates Src kinases by stimulating two related upstream tyrosine